Completion of recruitment of Part A of the NeflgArd pivotal Phase 3 clinical trial by year end December 19, 2019 08:00 CET Regulatory Read more
China IND approval triggers $5 million milestone payment from Everest Medicines December 17, 2019 11:40 CET Regulatory Read more
Calliditas Therapeutics’ nomination committee for the AGM 2020 November 11, 2019 10:00 CET Regulatory Read more
Positive interactions with EMA provide route to conditional marketing authorization of lead candidate Nefecon October 1, 2019 08:00 CET Regulatory Read more
Positive feedback from FDA significantly benefits ongoing NefIgArd pivotal Phase 3 study September 3, 2019 07:00 CET Regulatory Read more
Strategic in-licensing related to autoimmune hepatitis in the US market August 12, 2019 14:40 CET Regulatory Read more
Calliditas has resolved on a directed share issue in the amount of 3.5 million shares, raising proceeds of approximately SEK 210 million July 3, 2019 08:00 CET Regulatory Read more
Calliditas Therapeutics and Everest Medicines Enter into an Agreement to Develop and Commercialize Nefecon for IgA Nephropathy in Greater China and Singapore June 10, 2019 08:00 CET Regulatory Read more
Bulletin from the annual general meeting of Calliditas Therapeutics AB (publ) May 8, 2019 18:30 CET Regulatory Read more
Notice of annual general meeting of Calliditas Therapeutics AB (publ) April 4, 2019 09:01 CET Regulatory Read more
Calliditas Therapeutics granted orphan drug designation by the FDA for Primary biliary cholangitis February 12, 2019 11:15 CET Regulatory Read more
Calliditas Therapeutics granted orphan drug designation by the FDA for Autoimmune hepatitis February 5, 2019 10:15 CET Regulatory Read more